Long-term benefit of hepatitis B vaccination among children in Thailand with transient hepatitis B virus infection who were born to hepatitis B surface antigen-positive mothers

Journal of Infectious Diseases

Volumn 200, Issue 1, 2009, Pages 33-38

  Poovorawan, Yong ^a   Chongsrisawat, Voranush ^a   Theamboonlers, Apiradee ^a   Srinivasa, Karthik ^c   Hutagalung, Yanee ^b   Bock, Hans L ^d   Hoet, Bernard ^d  

^a CHULALONGKORN UNIVERSITY   (Thailand)

^b GlaxoSmiMline Biologicals   (Thailand)

^c GlaxoSmiMline Biologicals   (India)

^d GLAXOSMITHKLINE BIOLOGICALS   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

HEPATITIS B CORE ANTIBODY; HEPATITIS B SURFACE ANTIBODY; HEPATITIS B SURFACE ANTIGEN; HEPATITIS B VACCINE; HEPATITIS B(E) ANTIGEN; RECOMBINANT HEPATITIS B VACCINE;

ANTIBODY DETECTION; ANTIBODY RESPONSE; ARTICLE; FOLLOW UP; HEPATITIS B; HEPATITIS B VIRUS; HUMAN; INFECTION PREVENTION; LIVER DISEASE; MAJOR CLINICAL STUDY; MOTHER; NEWBORN; PRIORITY JOURNAL; SEROLOGY; THAILAND; VACCINATION; VIRUS CARRIER; VIRUS DETECTION; VIRUS TRANSMISSION;

CHILD; FEMALE; HEPATITIS B; HEPATITIS B E ANTIGENS; HEPATITIS B SURFACE ANTIGENS; HEPATITIS B VACCINES; HUMANS; IMMUNIZATION, SECONDARY; INFECTIOUS DISEASE TRANSMISSION, VERTICAL; PREGNANCY; THAILAND;

EID: 67650682776     PISSN: 00221899     EISSN: None     Source Type: Journal    
DOI: 10.1086/599331     Document Type: Article

References (24)

1. Beasley RP, Hwang LY. Hepatocellular carcinoma and hepatitis B virus. Semin Liver Dis 1984;4:113-21.
2. Poovorawan Y, Theamboonlers A, Vimolket T, et al. Impact of hepatitis B immunization as part of the EPI. Vaccine 2000; 19:943-9.
3. Goldstein ST, Zhou F, Hadler SC, et al. A mathematical model to estimate global hepatitis B disease burden and vaccination impact. Int J Epidemiol 2005;34:1329-39.
4. Beasley RP, Hwang LY. Overview of the epidemiology of hepatocellular carcinoma. In: Hollinger FB, Lemon SM, Margolis HS, eds. Viral hepatitis and liver disease: proceedings of the 1990 International Symposium on Viral Hepatitis and Liver Disease. Contemporary Issues and Future Prospects. Baltimore, MD: Williams & Wilkins, 1991:532-5.
5. Beasley RP. Hepatitis B virus: the major etiology of hepatocellular carcinoma. Cancer 1988;61:1942-56.
6. Lolekha S, Warachit B, Hirunyachote A Bowonkiratikachom P, West DJ, Poerschke G. Protective efficacy of hepatitis B vaccine without HBIG in infants of HBeAg-positive carrier mothers in Thailand. Vaccine 2002;20:3739-43.
7. Mast EE, Ward JW Hepatitis B vaccines. In: Plotkin SA Orenstein WA Offitt PA, eds. Vaccines. 5th ed. Philadelphia, PA: Elsevier, 2008: 205-41.
8. Beasley RP, Trepo Q Stevens CE, et al. The e antigen and vertical transmission of HBsAg. Am J Epidemiol 1977; 105:94-8.
9. Mast EE, Margolis HS, Fiore AE, et al. A comprehensive immunization strategy to eliminate transmission of hepatitis B virus infection in the United States: recommendations of the Advisory Committee on Immunization Practices (ACIP) part 1: immunization of infants, children, and adolescents. MMWR Recomm Rep 2005;54(RR-16):1-31.
10. Kane M. Global programme for control of hepatitis B infection. Vaccine 1995; 13:S47-9.
11. World Health Organization. Expanded programme on immunization: Global Advisory Group-part 1. Wkly Epidemiol Rec 1992;67:11-5.
12. Poovorawan Y, Sanapavat S, Pongpunglert W, et al. Long-term efficacy of hepatitis B vaccine in infants born to hepatitis B e antigen positive mothers. Pediatr Infect Dis J 1992; 11:816-21.
13. Poovorawan Y, Sanpavat S, Chumdermpadetsuk S, Safary A. Longterm hepatitis B vaccine in infants born to hepatitis B e antigen positive mothers. Arch Dis Child Fetal Neonatal Ed 1997;77:F47-51.
14. Poovorawan Y, Sanpavat S, Pongpunglert W, et al. Comparison of recombinant DNA hepatitis B vaccine alone or in combination with hepatitis B immune globulin for the prevention of perinatal acquisition of hepatitis B carriage. Vaccine 1990;8(Suppl):S56-9.
15. Poovorawan Y, Sanpavat S, Pongpunlert W, et al. Protective efficacy of a recombinant DNA hepatitis B vaccine in neonates of HBe antigen positive mothers. JAMA 1989;261:3278-81.
16. Poovorawan Y, Chongsrisawat V, Hutagalung Y, Srinavasa K, Hoet B. Long-term efficacy of hepatitis B vaccination of newborns born of hepatitis B surface antigen-positive mothers in Thailand [abstract P522]. In: Program and abstracts of the 12th International Symposium on Viral Hepatitis and Liver Disease, 1-5 July 2006 (Paris, France).
17. Pol S, Michel ML. Therapeutic vaccination in chronic hepatitis B virus carriers. Expert Rev Vaccines 2006; 5:707-16.
18. Hou J, Wang Z, Cheng J, et al. Prevalence of naturally occurring surface gene variants of hepatitis B virus in nonimmunized surface antigennegative Chinese carriers. Hepatology 2001;34:1027-34.
19. Hu KQ. Occult hepatitis B virus infection and its clinical implications. J Viral Hepat 2002;9:243-57.
20. Dentico P, Crovari P, Lai PL. Anamnestic response to administration of purified non-adsorbed hepatitis B surface antigen in healthy responden to hepatitis B vaccine with long-term protective antibody titers. Vaccine 2002; 20:3725-30.
21. Banatvala J, Van Damme P, Oehen S. Lifelong protection against hep-atitis B: the role of immunogenicity in immune memory. Vaccine 2000; 19:877-85.
22. Dentinger CM, McMahon BJ, Butler JC, et al. Persistence of antibody to hepatitis B and protection from disease among Alaska natives immunized at birth. Pediatr Infect Dis J 2005; 24:786-92.
23. Banatvala JE, Van Damme P. Hepatitis B vaccine- do we need boosters? J Viral Hepat 2003; 10:1-6.
24. Zanetti AR, Marian A, Romano L, et al. Long-term immunogenicity of hepatitis B vaccination and policy for booster: an Italian multicentre study. Lancet 2005;366:1379-84.